3B Pharmaceuticals and TetraKit Technologies announce strategic collaboration for joint radioligand therapy (RLT) development

CAR-T Digest - August 2020

10 April 2026: 3B Pharmaceuticals and TetraKit Technologies announce strategic collaboration for joint radioligand therapy (RLT) development

3B Pharmaceuticals GmbH and TetraKit Technologies have entered into a strategic collaboration to jointly develop radioligand therapies, focusing on advancing targeted radiotherapy approaches for cancer treatment
The partnership combines 3B Pharmaceuticals’ expertise in radiopharmaceutical drug discovery with TetraKit’s click chemistry-based radiolabeling platform to enable the development of innovative therapeutic candidates
By leveraging their respective platforms, the collaboration aims to develop a novel drug candidate labeled with astatine-211 and advance this emerging class of radiopharmaceutical therapies
This approach aims to support the advancement of peptide-based radiopharmaceuticals by enabling precise delivery of radiation to tumor cells while minimizing damage to healthy tissues